Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Apellis Pharmaceuticals, Inc. (APLS) since 2017 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Apellis Pharmaceuticals, Inc.. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 1492422.
Total stock buying since 2017: $72,055,913.
Total stock sales since 2017: $125,480,225.
Total stock option exercises since 2017: $17,781,278.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 498,012 | $12,822,188 | 87,780 | $371,300 |
| 2024 | 0 | $0 | 440,133 | $23,511,567 | 261,584 | $1,202,259 |
| 2023 | 0 | $0 | 757,461 | $46,600,892 | 1,306,608 | $7,793,855 |
| 2022 | 0 | $0 | 270,047 | $14,741,673 | 328,866 | $3,017,705 |
| 2021 | 250,000 | $10,000,000 | 95,771 | $4,885,298 | 354,966 | $2,429,947 |
| 2020 | 545,540 | $20,159,015 | 399,824 | $16,235,156 | 579,554 | $1,976,550 |
| 2019 | 452,875 | $7,847,627 | 230,001 | $6,387,115 | 327,505 | $723,388 |
| 2018 | 224,258 | $4,214,067 | 15,776 | $296,336 | 98,302 | $266,274 |
| 2017 | 2,131,086 | $29,835,204 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-09-01 | Francois Cedric (Chief Executive Officer) | Sale | 150,000 | 42.07 | 6,310,650 |
| 2023-09-01 | Francois Cedric (Chief Executive Officer) | Option Ex | 300,000 | 2.67 | 801,000 |
| 2023-08-31 | Chopas James George (VP/Chief Accounting Officer) | Sale | 551 | 41.23 | 22,715 |
| 2023-08-08 | Deschatelets Pascal (Chief Scientific Officer) | Sale | 12,000 | 23.66 | 283,920 |
| 2023-08-08 | Deschatelets Pascal (Chief Scientific Officer) | Option Ex | 18,500 | 2.67 | 49,395 |
| 2023-07-21 | Machiels Alec (Director) | Option Ex | 49,779 | 2.67 | 132,909 |
| 2023-07-20 | Machiels Alec (Director) | Option Ex | 50,000 | 2.67 | 133,500 |
| 2023-07-17 | Machiels Alec (Director) | Sale | 1,250 | 64.79 | 80,987 |
| 2023-07-17 | Machiels Alec (Director) | Option Ex | 1,250 | 2.67 | 3,337 |
| 2023-07-10 | Deschatelets Pascal (Chief Scientific Officer) | Sale | 12,000 | 84.55 | 1,014,600 |
| 2023-07-10 | Deschatelets Pascal (Chief Scientific Officer) | Option Ex | 18,500 | 2.67 | 49,395 |
| 2023-07-03 | Sullivan Timothy Eugene (Chief Financial Officer) | Sale | 6,779 | 90.31 | 612,204 |
| 2023-07-03 | Sullivan Timothy Eugene (Chief Financial Officer) | Option Ex | 6,779 | 10.03 | 67,993 |
| 2023-07-03 | Watson David O. (General Counsel) | Sale | 8,510 | 89.98 | 765,729 |
| 2023-06-20 | Machiels Alec (Director) | Sale | 1,250 | 88.41 | 110,512 |
| 2023-06-20 | Machiels Alec (Director) | Option Ex | 1,250 | 2.67 | 3,337 |
| 2023-06-08 | Deschatelets Pascal (Chief Scientific Officer) | Sale | 12,000 | 91.35 | 1,096,200 |
| 2023-06-08 | Deschatelets Pascal (Chief Scientific Officer) | Option Ex | 18,500 | 2.67 | 49,395 |
| 2023-06-05 | Sullivan Timothy Eugene (Chief Financial Officer) | Sale | 69,779 | 89.15 | 6,220,518 |
| 2023-06-05 | Sullivan Timothy Eugene (Chief Financial Officer) | Option Ex | 69,779 | 10.03 | 699,883 |
| 2023-06-01 | Lewis Karen (Chief People Officer) | Sale | 10,000 | 86.00 | 860,000 |
| 2023-06-01 | Lewis Karen (Chief People Officer) | Option Ex | 10,000 | 34.11 | 341,100 |
| 2023-05-17 | Francois Cedric (Chief Executive Officer) | Option Ex | 20,000 | 2.67 | 53,400 |
| 2023-05-17 | Machiels Alec (Director) | Sale | 1,250 | 88.66 | 110,825 |
| 2023-05-17 | Machiels Alec (Director) | Option Ex | 1,250 | 2.67 | 3,337 |
| 2023-05-16 | Francois Cedric (Chief Executive Officer) | Sale | 30,000 | 85.44 | 2,563,080 |
| 2023-05-16 | Francois Cedric (Chief Executive Officer) | Option Ex | 30,000 | 2.67 | 80,100 |
| 2023-05-08 | Deschatelets Pascal (Chief Scientific Officer) | Sale | 12,000 | 92.39 | 1,108,680 |
| 2023-05-08 | Deschatelets Pascal (Chief Scientific Officer) | Option Ex | 18,500 | 2.67 | 49,395 |
| 2023-05-03 | Townsend Adam J. (Chief Commercial Officer) | Sale | 5,000 | 82.71 | 413,549 |
| 2023-05-03 | Townsend Adam J. (Chief Commercial Officer) | Option Ex | 5,000 | 15.09 | 75,450 |
| 2023-04-19 | Francois Cedric (Chief Executive Officer) | Option Ex | 20,000 | 2.67 | 53,400 |
| 2023-04-18 | Francois Cedric (Chief Executive Officer) | Sale | 30,000 | 82.02 | 2,460,720 |
| 2023-04-18 | Francois Cedric (Chief Executive Officer) | Option Ex | 30,000 | 2.67 | 80,100 |
| 2023-04-17 | Machiels Alec (Director) | Sale | 1,250 | 81.05 | 101,312 |
| 2023-04-17 | Machiels Alec (Director) | Option Ex | 1,250 | 2.67 | 3,337 |
| 2023-04-10 | Deschatelets Pascal (Chief Scientific Officer) | Sale | 12,000 | 78.21 | 938,519 |
| 2023-04-10 | Deschatelets Pascal (Chief Scientific Officer) | Option Ex | 18,500 | 2.67 | 49,395 |
| 2023-04-03 | Lewis Karen (Chief People Officer) | Sale | 5,000 | 75.00 | 375,000 |
| 2023-04-03 | Lewis Karen (Chief People Officer) | Option Ex | 5,000 | 34.11 | 170,550 |
| 2023-04-03 | Townsend Adam J. (Chief Commercial Officer) | Sale | 5,000 | 74.05 | 370,250 |
| 2023-04-03 | Townsend Adam J. (Chief Commercial Officer) | Option Ex | 5,000 | 15.09 | 75,450 |
| 2023-04-03 | Dunlop A. Sinclair (Director) | Sale | 500 | 74.05 | 37,025 |
| 2023-03-22 | Francois Cedric (Chief Executive Officer) | Option Ex | 127,221 | 6.76 | 860,013 |
| 2023-03-21 | Francois Cedric (Chief Executive Officer) | Sale | 30,000 | 62.74 | 1,882,320 |
| 2023-03-21 | Francois Cedric (Chief Executive Officer) | Option Ex | 30,000 | 2.67 | 80,100 |
| 2023-03-17 | Machiels Alec (Director) | Sale | 1,250 | 64.03 | 80,037 |
| 2023-03-17 | Machiels Alec (Director) | Option Ex | 1,250 | 2.67 | 3,337 |
| 2023-03-08 | Deschatelets Pascal (Chief Scientific Officer) | Sale | 12,000 | 63.79 | 765,480 |
| 2023-03-08 | Deschatelets Pascal (Chief Scientific Officer) | Option Ex | 18,500 | 2.67 | 49,395 |
| 2023-03-03 | Townsend Adam J. (Chief Commercial Officer) | Sale | 5,000 | 63.84 | 319,200 |
| 2023-03-03 | Townsend Adam J. (Chief Commercial Officer) | Option Ex | 5,000 | 15.09 | 75,450 |
| 2023-03-01 | Dunlop A. Sinclair (Director) | Sale | 500 | 65.33 | 32,665 |
| 2023-02-27 | Francois Cedric (Chief Executive Officer) | Option Ex | 100,000 | 3.76 | 376,000 |
| 2023-02-23 | Eisele Jeffrey (Chief Development Officer) | Sale | 1,646 | 68.76 | 113,178 |
| 2023-02-23 | Lewis Karen (Chief People Officer) | Sale | 1,104 | 68.76 | 75,911 |
| 2023-02-17 | Machiels Alec (Director) | Sale | 1,250 | 52.38 | 65,475 |
| 2023-02-17 | Machiels Alec (Director) | Option Ex | 1,250 | 2.67 | 3,337 |
| 2023-02-08 | Deschatelets Pascal (Chief Scientific Officer) | Sale | 12,000 | 54.45 | 653,400 |
| 2023-02-08 | Deschatelets Pascal (Chief Scientific Officer) | Option Ex | 18,500 | 2.67 | 49,395 |
| 2023-02-03 | Townsend Adam J. (Chief Commercial Officer) | Sale | 5,000 | 55.85 | 279,250 |
| 2023-02-03 | Townsend Adam J. (Chief Commercial Officer) | Option Ex | 5,000 | 15.09 | 75,450 |
| 2023-02-01 | Dunlop A. Sinclair (Director) | Sale | 500 | 52.61 | 26,305 |
| 2023-01-30 | Eisele Jeffrey (Chief Development Officer) | Sale | 883 | 52.76 | 46,587 |
| 2023-01-30 | Lewis Karen (Chief People Officer) | Sale | 883 | 52.76 | 46,587 |
| 2023-01-09 | Deschatelets Pascal (Chief Scientific Officer) | Sale | 12,000 | 46.08 | 552,960 |
| 2023-01-09 | Deschatelets Pascal (Chief Scientific Officer) | Option Ex | 18,500 | 2.67 | 49,395 |
| 2023-01-05 | Grossi Federico (Chief Medical Officer) | Sale | 2,500 | 48.79 | 121,975 |
| 2023-01-03 | Townsend Adam J. (Chief Commercial Officer) | Sale | 10,000 | 50.70 | 507,000 |
| 2023-01-03 | Townsend Adam J. (Chief Commercial Officer) | Option Ex | 10,000 | 15.09 | 150,900 |
| 2023-01-03 | Dunlop A. Sinclair (Director) | Sale | 1,000 | 50.70 | 50,700 |
| 2022-12-29 | Deschatelets Pascal (Chief Scientific Officer) | Option Ex | 7,000 | 3.67 | 25,690 |
| 2022-12-05 | Townsend Adam J. (Chief Commercial Officer) | Sale | 5,000 | 50.38 | 251,900 |
| 2022-12-05 | Townsend Adam J. (Chief Commercial Officer) | Option Ex | 5,000 | 15.09 | 75,450 |
| 2022-11-15 | Machiels Alec (Director) | Sale | 1,250 | 48.01 | 60,012 |
| 2022-11-15 | Machiels Alec (Director) | Option Ex | 1,250 | 2.67 | 3,337 |
| 2022-11-08 | Deschatelets Pascal (Chief Scientific Officer) | Sale | 12,000 | 46.47 | 557,640 |
| 2022-11-08 | Deschatelets Pascal (Chief Scientific Officer) | Option Ex | 18,500 | 2.67 | 49,395 |
| 2022-11-03 | Townsend Adam J. (Chief Commercial Officer) | Sale | 5,000 | 58.54 | 292,700 |
| 2022-11-03 | Townsend Adam J. (Chief Commercial Officer) | Option Ex | 5,000 | 15.09 | 75,450 |
| 2022-10-14 | Machiels Alec (Director) | Sale | 2,500 | 59.31 | 148,274 |
| 2022-10-14 | Machiels Alec (Director) | Option Ex | 2,500 | 2.67 | 6,674 |
| 2022-10-03 | Townsend Adam J. (Chief Commercial Officer) | Sale | 5,000 | 66.69 | 333,450 |
| 2022-10-03 | Townsend Adam J. (Chief Commercial Officer) | Option Ex | 5,000 | 15.09 | 75,450 |
| 2022-10-03 | Grossi Federico (CHIEF MEDICAL OFFICER) | Sale | 2,500 | 66.69 | 166,725 |
| 2022-09-15 | Machiels Alec (Director) | Sale | 1,250 | 66.00 | 82,500 |
| 2022-09-15 | Machiels Alec (Director) | Option Ex | 1,250 | 2.67 | 3,337 |
| 2022-09-08 | Deschatelets Pascal (Chief Scientific Officer) | Sale | 12,000 | 63.98 | 767,760 |
| 2022-09-08 | Deschatelets Pascal (Chief Scientific Officer) | Option Ex | 18,500 | 2.67 | 49,395 |
| 2022-08-17 | Delong Mark Jeffrey (Senior Vice President) | Sale | 5,000 | 69.50 | 347,500 |
| 2022-08-17 | Delong Mark Jeffrey (Senior Vice President) | Option Ex | 5,000 | 15.52 | 77,600 |
| 2022-08-16 | Dunlop A. Sinclair (Director) | Option Ex | 25,394 | 14.00 | 355,516 |
| 2022-08-15 | Townsend Adam J. (Chief Commercial Officer) | Sale | 12,500 | 69.00 | 862,500 |
| 2022-08-15 | Townsend Adam J. (Chief Commercial Officer) | Option Ex | 12,500 | 15.09 | 188,625 |
| 2022-08-15 | Machiels Alec (Director) | Sale | 1,250 | 67.21 | 84,012 |
| 2022-08-15 | Machiels Alec (Director) | Option Ex | 1,250 | 2.67 | 3,337 |
| 2022-08-11 | Delong Mark Jeffrey (Senior Vice President) | Sale | 5,000 | 67.00 | 335,000 |
| 2022-08-11 | Delong Mark Jeffrey (Senior Vice President) | Option Ex | 5,000 | 15.52 | 77,600 |
| 2022-08-11 | Townsend Adam J. (Chief Commercial Officer) | Sale | 12,500 | 67.00 | 837,500 |
| 2022-08-11 | Townsend Adam J. (Chief Commercial Officer) | Option Ex | 12,500 | 15.09 | 188,625 |
| 2022-08-11 | Dunlop A. Sinclair (Director) | Sale | 30,000 | 65.63 | 1,968,899 |
| 2022-08-04 | Delong Mark Jeffrey (Senior Vice President) | Sale | 10,000 | 60.75 | 607,500 |
| 2022-08-04 | Delong Mark Jeffrey (Senior Vice President) | Option Ex | 10,000 | 15.52 | 155,200 |
| 2022-08-03 | Townsend Adam J. (Chief Commercial Officer) | Sale | 5,000 | 56.43 | 282,150 |
| 2022-08-03 | Townsend Adam J. (Chief Commercial Officer) | Option Ex | 5,000 | 15.09 | 75,450 |
| 2022-08-01 | Grossi Federico (CHIEF MEDICAL OFFICER) | Sale | 2,500 | 55.99 | 139,975 |
| 2022-07-27 | Delong Mark Jeffrey (Senior Vice President) | Sale | 5,000 | 57.00 | 285,000 |
| 2022-07-27 | Delong Mark Jeffrey (Senior Vice President) | Option Ex | 5,000 | 15.52 | 77,600 |
| 2022-07-21 | Dunlop A. Sinclair (Director) | Option Ex | 9,606 | 14.00 | 134,484 |
| 2022-07-19 | Delong Mark Jeffrey (Senior Vice President) | Sale | 5,000 | 56.42 | 282,100 |
| 2022-07-19 | Delong Mark Jeffrey (Senior Vice President) | Option Ex | 5,000 | 15.52 | 77,600 |
| 2022-07-15 | Machiels Alec (Director) | Sale | 1,250 | 46.33 | 57,912 |
| 2022-07-15 | Machiels Alec (Director) | Option Ex | 1,250 | 2.67 | 3,337 |
| 2022-07-11 | Townsend Adam J. (Chief Commercial Officer) | Sale | 5,000 | 48.42 | 242,100 |
| 2022-07-11 | Townsend Adam J. (Chief Commercial Officer) | Option Ex | 5,000 | 15.09 | 75,450 |
| 2022-07-08 | Deschatelets Pascal (Chief Scientific Officer) | Sale | 12,000 | 47.95 | 575,400 |
| 2022-07-08 | Deschatelets Pascal (Chief Scientific Officer) | Option Ex | 18,500 | 2.67 | 49,395 |
| 2022-06-27 | Dunlop A. Sinclair (Director) | Sale | 1,341 | 46.79 | 62,742 |
| 2022-06-23 | Dunlop A. Sinclair (Director) | Sale | 15,000 | 45.00 | 675,000 |
| 2022-06-22 | Watson David O. (General Counsel) | Sale | 10,000 | 44.51 | 445,140 |
| 2022-06-17 | Brown Victoria L. (Program Team Lead) | Sale | 2,698 | 45.00 | 121,410 |
| 2022-06-17 | Deschatelets Pascal (Chief Scientific Officer) | Option Ex | 33,005 | 2.67 | 88,123 |
| 2022-06-16 | Delong Mark Jeffrey (Senior Vice President) | Sale | 10,000 | 41.78 | 417,849 |
| 2022-06-16 | Delong Mark Jeffrey (Senior Vice President) | Option Ex | 10,000 | 13.85 | 138,500 |
| 2022-06-15 | Machiels Alec (Director) | Sale | 1,250 | 39.29 | 49,112 |
| 2022-06-15 | Machiels Alec (Director) | Option Ex | 1,250 | 2.67 | 3,337 |
| 2022-06-08 | Deschatelets Pascal (Chief Scientific Officer) | Sale | 12,000 | 44.09 | 529,080 |
| 2022-06-08 | Deschatelets Pascal (Chief Scientific Officer) | Option Ex | 18,500 | 2.67 | 49,395 |
| 2022-06-01 | Grossi Federico (CHIEF MEDICAL OFFICER) | Sale | 2,500 | 41.78 | 104,450 |
| 2022-05-27 | Scheibler Lukas (CHIEF INNOVATION OFFICER) | Sale | 10,000 | 43.00 | 430,000 |
| 2022-05-16 | Machiels Alec (Director) | Sale | 1,250 | 39.18 | 48,975 |
| 2022-05-16 | Machiels Alec (Director) | Option Ex | 1,250 | 2.67 | 3,337 |
| 2022-05-02 | Grossi Federico (CHIEF MEDICAL OFFICER) | Sale | 2,500 | 43.56 | 108,900 |
| 2022-04-29 | Deschatelets Pascal (Chief Scientific Officer) | Sale | 4,000 | 44.43 | 177,720 |
| 2022-04-29 | Deschatelets Pascal (Chief Scientific Officer) | Option Ex | 4,000 | 2.67 | 10,680 |
| 2022-04-25 | Watson David O. (General Counsel) | Sale | 5,000 | 50.00 | 250,000 |
| 2022-04-22 | Dunlop A. Sinclair (Director) | Option Ex | 20,000 | 14.00 | 280,000 |
| 2022-04-20 | Delong Mark Jeffrey (Senior Vice President) | Sale | 7,000 | 52.53 | 367,710 |
| 2022-04-20 | Delong Mark Jeffrey (Senior Vice President) | Option Ex | 7,000 | 15.52 | 108,640 |
| 2022-04-14 | Machiels Alec (Director) | Sale | 1,250 | 50.90 | 63,625 |
| 2022-04-14 | Machiels Alec (Director) | Option Ex | 1,250 | 2.67 | 3,337 |
| 2022-04-05 | Scheibler Lukas (CHIEF INNOVATION OFFICER) | Sale | 609 | 60.09 | 36,592 |
| 2022-04-05 | Scheibler Lukas (CHIEF INNOVATION OFFICER) | Option Ex | 609 | 13.85 | 8,434 |
| 2022-04-04 | Scheibler Lukas (CHIEF INNOVATION OFFICER) | Sale | 3,504 | 56.84 | 199,153 |
| 2022-04-04 | Scheibler Lukas (CHIEF INNOVATION OFFICER) | Option Ex | 3,504 | 13.85 | 48,530 |
| 2022-04-01 | Scheibler Lukas (CHIEF INNOVATION OFFICER) | Sale | 11,496 | 55.05 | 632,854 |
| 2022-04-01 | Scheibler Lukas (CHIEF INNOVATION OFFICER) | Option Ex | 11,496 | 13.85 | 159,219 |
| 2022-03-15 | Grossi Federico (CHIEF MEDICAL OFFICER) | Sale | 375 | 39.57 | 14,838 |
| 2022-03-15 | Grossi Federico (CHIEF MEDICAL OFFICER) | Option Ex | 7,000 | 4.31 | 30,169 |
| 2022-03-15 | Machiels Alec (Director) | Sale | 1,250 | 39.57 | 49,462 |
Insider trading activities including stock purchases, stock sales, and option exercises of APLS listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Apellis Pharmaceuticals, Inc. (symbol APLS, CIK number 1492422) see the Securities and Exchange Commission (SEC) website.